Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses

Huang, Tianguang; Sun, Lin; Kang, Dongwei; Poongavanam, Vasanthanathan; Liu, Xinyong; Zhan, Peng; Menéndez‐Arias, Luis

doi:10.1007/978-981-16-0267-2_9

Cited by 5 publications

(1 citation statement)

References 226 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most recent promising treatment for cats with FIP is the use of the nucleoside analogue GS-441524 [24,25,28], which is the active form of the prodrug remdesivir [29]. Currently, remdesivir is only conditionally licensed to treat human patients with severe COVID-19 symptoms [30][31][32]. Cats in these prospective studies received GS-441524 subcutaneously for various time periods and owners were instructed by social media groups to inject the compounds likewise for a period of 12 weeks or longer.…”

Section: Introductionmentioning

confidence: 99%

Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524

Krentz¹,

Zenger²,

Alberer³

et al. 2021

Viruses

107

View full text Add to dashboard Cite

Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn® in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn®. Eighteen cats with FIP were prospectively followed up while being treated orally for 84 days. Values of key parameters on each examination day were compared to values before treatment initiation using linear mixed-effect models. Xraphconn® displayed high virucidal activity in cell culture. All cats recovered with dramatic improvement of clinical and laboratory parameters and massive reduction in viral loads within the first few days of treatment without serious adverse effects. Oral treatment with Xraphconn® containing GS-441524 was highly effective for FIP without causing serious adverse effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potential effective treatment option for other severe coronavirus-associated diseases across species.

show abstract